array(40) {
  [0]=>
  string(4) "9259"
  ["article_id"]=>
  string(4) "9259"
  [1]=>
  string(92) "7th European Conference on Clinical Research: Pushing Boundaries and Accelerating Innovation"
  ["article_title"]=>
  string(92) "7th European Conference on Clinical Research: Pushing Boundaries and Accelerating Innovation"
  [2]=>
  string(150) "EUCROF24 will bring together pharma, biotech, medical device companies, CROs and other service providers, technology providers, regulators, patients, "
  ["short_description"]=>
  string(150) "EUCROF24 will bring together pharma, biotech, medical device companies, CROs and other service providers, technology providers, regulators, patients, "
  [3]=>
  string(500) "EUCROF24 will bring together pharma, biotech, medical device companies, CROs and other service providers, technology providers, regulators, patients, and academia, to discuss the current challenges, and future direction of Clinical Research across Europe. EUCROF24 is the 7th running of the EUCROF Clinical Research Conference that attracts a diverse range of speakers and attendees from functions including clinical operations, regulatory, data management, statistics, medical and safety, digital..."
  ["description"]=>
  string(500) "EUCROF24 will bring together pharma, biotech, medical device companies, CROs and other service providers, technology providers, regulators, patients, and academia, to discuss the current challenges, and future direction of Clinical Research across Europe. EUCROF24 is the 7th running of the EUCROF Clinical Research Conference that attracts a diverse range of speakers and attendees from functions including clinical operations, regulatory, data management, statistics, medical and safety, digital..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(123) "https://www.pharmiweb.com/event/7th-european-conference-on-clinical-research-pushing-boundaries-and-accelerating-innovation"
  ["blog_url"]=>
  string(123) "https://www.pharmiweb.com/event/7th-european-conference-on-clinical-research-pushing-boundaries-and-accelerating-innovation"
  [15]=>
  string(19) "2023-12-06 11:20:45"
  ["add_date"]=>
  string(19) "2023-12-06 11:20:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:55"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:55"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9076"
  ["article_id"]=>
  string(4) "9076"
  [1]=>
  string(169) "Bridgebio Pharma Announces Submission of New Drug Application to the FDA for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)"
  ["article_title"]=>
  string(169) "Bridgebio Pharma Announces Submission of New Drug Application to the FDA for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)"
  [2]=>
  string(153) "&#nlNDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a W"
  ["short_description"]=>
  string(153) "&#nlNDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a W"
  [3]=>
  string(251) "&#nlNDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), on the primary endpoint (a hierarchical analysis prioritizing in..."
  ["description"]=>
  string(251) "&#nlNDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), on the primary endpoint (a hierarchical analysis prioritizing in..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(48) "https://www.drugs.com/nda/acoramidis_231205.html"
  ["blog_url"]=>
  string(48) "https://www.drugs.com/nda/acoramidis_231205.html"
  [15]=>
  string(19) "2023-12-06 01:12:15"
  ["add_date"]=>
  string(19) "2023-12-06 01:12:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9077"
  ["article_id"]=>
  string(4) "9077"
  [1]=>
  string(150) "Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis"
  ["article_title"]=>
  string(150) "Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis"
  [2]=>
  string(150) "WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration "
  ["short_description"]=>
  string(150) "WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration "
  [3]=>
  string(248) "WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the..."
  ["description"]=>
  string(248) "WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(49) "https://www.drugs.com/nda/tradipitant_231204.html"
  ["blog_url"]=>
  string(49) "https://www.drugs.com/nda/tradipitant_231204.html"
  [15]=>
  string(19) "2023-12-05 01:12:14"
  ["add_date"]=>
  string(19) "2023-12-05 01:12:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9078"
  ["article_id"]=>
  string(4) "9078"
  [1]=>
  string(137) "Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia"
  ["article_title"]=>
  string(137) "Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia"
  [2]=>
  string(150) "BOSTON--(BUSINESS WIRE)--Nov. 29, 2023-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and delive"
  ["short_description"]=>
  string(150) "BOSTON--(BUSINESS WIRE)--Nov. 29, 2023-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and delive"
  [3]=>
  string(249) "BOSTON--(BUSINESS WIRE)--Nov. 29, 2023-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today..."
  ["description"]=>
  string(249) "BOSTON--(BUSINESS WIRE)--Nov. 29, 2023-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(43) "https://www.drugs.com/nda/karxt_231129.html"
  ["blog_url"]=>
  string(43) "https://www.drugs.com/nda/karxt_231129.html"
  [15]=>
  string(19) "2023-11-30 02:11:46"
  ["add_date"]=>
  string(19) "2023-11-30 02:11:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9079"
  ["article_id"]=>
  string(4) "9079"
  [1]=>
  string(65) "Italfarmaco Group Announces New PDUFA Date for Givinostat DMD NDA"
  ["article_title"]=>
  string(65) "Italfarmaco Group Announces New PDUFA Date for Givinostat DMD NDA"
  [2]=>
  string(150) "MILAN--(BUSINESS WIRE) November 29, 2023 --Italfarmaco Group announced today that the U.S. Food and Drug Administration (FDA) has extended the review "
  ["short_description"]=>
  string(150) "MILAN--(BUSINESS WIRE) November 29, 2023 --Italfarmaco Group announced today that the U.S. Food and Drug Administration (FDA) has extended the review "
  [3]=>
  string(250) "MILAN--(BUSINESS WIRE) November 29, 2023 --Italfarmaco Group announced today that the U.S. Food and Drug Administration (FDA) has extended the review process of the New Drug Application (NDA) for Givinostat, the company’s proprietary histone..."
  ["description"]=>
  string(250) "MILAN--(BUSINESS WIRE) November 29, 2023 --Italfarmaco Group announced today that the U.S. Food and Drug Administration (FDA) has extended the review process of the New Drug Application (NDA) for Givinostat, the company’s proprietary histone..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(48) "https://www.drugs.com/nda/givinostat_231129.html"
  ["blog_url"]=>
  string(48) "https://www.drugs.com/nda/givinostat_231129.html"
  [15]=>
  string(19) "2023-11-29 08:11:55"
  ["add_date"]=>
  string(19) "2023-11-29 08:11:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9052"
  ["article_id"]=>
  string(4) "9052"
  [1]=>
  string(157) "FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and Clobazam (Onfi, Sympazan)"
  ["article_title"]=>
  string(157) "FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and Clobazam (Onfi, Sympazan)"
  [2]=>
  string(150) "Audience: Consumer, Health Professional November 28, 2023 -- FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (K"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional November 28, 2023 -- FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (K"
  [3]=>
  string(259) "Audience: Consumer, Health Professional November 28, 2023 -- FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and Clobazam (Onfi, Sympazan)&#nl&#nl&#nl&#nlWhat safety concern is..."
  ["description"]=>
  string(259) "Audience: Consumer, Health Professional November 28, 2023 -- FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and Clobazam (Onfi, Sympazan)&#nl&#nl&#nl&#nlWhat safety concern is..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(136) "https://www.drugs.com/fda/fda-warns-rare-but-serious-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr-14638.html"
  ["blog_url"]=>
  string(136) "https://www.drugs.com/fda/fda-warns-rare-but-serious-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr-14638.html"
  [15]=>
  string(19) "2023-11-28 16:13:00"
  ["add_date"]=>
  string(19) "2023-11-28 16:13:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9053"
  ["article_id"]=>
  string(4) "9053"
  [1]=>
  string(158) "FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies"
  ["article_title"]=>
  string(158) "FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies"
  [2]=>
  string(150) "Audience: Health Professional November 28, 2023 -- The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chime"
  ["short_description"]=>
  string(150) "Audience: Health Professional November 28, 2023 -- The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chime"
  [3]=>
  string(245) "Audience: Health Professional November 28, 2023 -- The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or..."
  ["description"]=>
  string(245) "Audience: Health Professional November 28, 2023 -- The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(134) "https://www.drugs.com/fda/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-cd19-directed-autologous-14637.html"
  ["blog_url"]=>
  string(134) "https://www.drugs.com/fda/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-cd19-directed-autologous-14637.html"
  [15]=>
  string(19) "2023-11-28 15:35:00"
  ["add_date"]=>
  string(19) "2023-11-28 15:35:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9080"
  ["article_id"]=>
  string(4) "9080"
  [1]=>
  string(174) "Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease"
  ["article_title"]=>
  string(174) "Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease"
  [2]=>
  string(156) "&#nlAdditional Trial Required to Demonstrate Positive Effect on the Treatment of Ocular Symptoms in Dry Eye Disease&#nlSpecial Protocol Assessment Submitted"
  ["short_description"]=>
  string(156) "&#nlAdditional Trial Required to Demonstrate Positive Effect on the Treatment of Ocular Symptoms in Dry Eye Disease&#nlSpecial Protocol Assessment Submitted"
  [3]=>
  string(251) "&#nlAdditional Trial Required to Demonstrate Positive Effect on the Treatment of Ocular Symptoms in Dry Eye Disease&#nlSpecial Protocol Assessment Submitted on November 16, 2023 for Dry Eye Disease Chamber Crossover Clinical Trial&#nlProposed Trial..."
  ["description"]=>
  string(251) "&#nlAdditional Trial Required to Demonstrate Positive Effect on the Treatment of Ocular Symptoms in Dry Eye Disease&#nlSpecial Protocol Assessment Submitted on November 16, 2023 for Dry Eye Disease Chamber Crossover Clinical Trial&#nlProposed Trial..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(48) "https://www.drugs.com/nda/reproxalap_231127.html"
  ["blog_url"]=>
  string(48) "https://www.drugs.com/nda/reproxalap_231127.html"
  [15]=>
  string(19) "2023-11-28 07:11:46"
  ["add_date"]=>
  string(19) "2023-11-28 07:11:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9054"
  ["article_id"]=>
  string(4) "9054"
  [1]=>
  string(175) "Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene"
  ["article_title"]=>
  string(175) "Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene"
  [2]=>
  string(150) "Audience: Consumer, Pharmacy TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company ("
  ["short_description"]=>
  string(150) "Audience: Consumer, Pharmacy TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company ("
  [3]=>
  string(245) "Audience: Consumer, Pharmacy TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 2% Miconazole Nitrate..."
  ["description"]=>
  string(245) "Audience: Consumer, Pharmacy TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 2% Miconazole Nitrate..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(136) "https://www.drugs.com/fda/insight-pharmaceuticals-issues-voluntary-nationwide-recall-ting-2-miconazole-nitrate-athlete-s-foot-14636.html"
  ["blog_url"]=>
  string(136) "https://www.drugs.com/fda/insight-pharmaceuticals-issues-voluntary-nationwide-recall-ting-2-miconazole-nitrate-athlete-s-foot-14636.html"
  [15]=>
  string(19) "2023-11-25 07:32:00"
  ["add_date"]=>
  string(19) "2023-11-25 07:32:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9055"
  ["article_id"]=>
  string(4) "9055"
  [1]=>
  string(158) "Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization"
  ["article_title"]=>
  string(158) "Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization"
  [2]=>
  string(150) "Audience: Health Professional, Pharmacy, Consumer November 24, 2023 - East Hanover, NJ — Novartis is conducting a voluntary nationwide recall at"
  ["short_description"]=>
  string(150) "Audience: Health Professional, Pharmacy, Consumer November 24, 2023 - East Hanover, NJ — Novartis is conducting a voluntary nationwide recall at"
  [3]=>
  string(250) "Audience: Health Professional, Pharmacy, Consumer November 24, 2023 - East Hanover, NJ — Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune® Oral Solution (cyclosporine oral solution,..."
  ["description"]=>
  string(250) "Audience: Health Professional, Pharmacy, Consumer November 24, 2023 - East Hanover, NJ — Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune® Oral Solution (cyclosporine oral solution,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(135) "https://www.drugs.com/fda/novartis-issues-voluntary-us-nationwide-recall-two-lots-sandimmune-oral-solution-cyclosporine-oral-14639.html"
  ["blog_url"]=>
  string(135) "https://www.drugs.com/fda/novartis-issues-voluntary-us-nationwide-recall-two-lots-sandimmune-oral-solution-cyclosporine-oral-14639.html"
  [15]=>
  string(19) "2023-11-24 16:38:00"
  ["add_date"]=>
  string(19) "2023-11-24 16:38:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9281"
  ["article_id"]=>
  string(4) "9281"
  [1]=>
  string(46) "Medical Device Company Opens Minnesota Factory"
  ["article_title"]=>
  string(46) "Medical Device Company Opens Minnesota Factory"
  [2]=>
  string(158) "&#nl        BLAINE, MN—Ascential Technologies, a manufacturer of custom automation for medical device manufacturers, has opened a new 100,000-square-fo"
  ["short_description"]=>
  string(158) "&#nl        BLAINE, MN—Ascential Technologies, a manufacturer of custom automation for medical device manufacturers, has opened a new 100,000-square-fo"
  [3]=>
  string(191) "&#nl        
BLAINE, MN—Ascential Technologies, a manufacturer of custom automation for medical device manufacturers, has opened a new 100,000-square-foot factory here.
&#nl      "
  ["description"]=>
  string(191) "&#nl        
BLAINE, MN—Ascential Technologies, a manufacturer of custom automation for medical device manufacturers, has opened a new 100,000-square-foot factory here.
&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(89) "https://www.assemblymag.com/articles/98156-medical-device-company-opens-minnesota-factory"
  ["blog_url"]=>
  string(89) "https://www.assemblymag.com/articles/98156-medical-device-company-opens-minnesota-factory"
  [15]=>
  string(19) "2023-11-22 03:10:00"
  ["add_date"]=>
  string(19) "2023-11-22 03:10:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:31"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:31"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9056"
  ["article_id"]=>
  string(4) "9056"
  [1]=>
  string(110) "FDA Warns Consumers Not To Purchase or Use Neptune’s Fix or Any Tianeptine Product Due To Serious Risks"
  ["article_title"]=>
  string(110) "FDA Warns Consumers Not To Purchase or Use Neptune’s Fix or Any Tianeptine Product Due To Serious Risks"
  [2]=>
  string(150) "Audience: Consumers November 21, 2023 -- FDA is warning consumers to not purchase or use any Neptune’s Fix products, or any other product with t"
  ["short_description"]=>
  string(150) "Audience: Consumers November 21, 2023 -- FDA is warning consumers to not purchase or use any Neptune’s Fix products, or any other product with t"
  [3]=>
  string(251) "Audience: Consumers November 21, 2023 -- FDA is warning consumers to not purchase or use any Neptune’s Fix products, or any other product with tianeptine -- a potentially dangerous substance that is not FDA-approved for any medical use but is..."
  ["description"]=>
  string(251) "Audience: Consumers November 21, 2023 -- FDA is warning consumers to not purchase or use any Neptune’s Fix products, or any other product with tianeptine -- a potentially dangerous substance that is not FDA-approved for any medical use but is..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(124) "https://www.drugs.com/fda/fda-warns-consumers-not-purchase-neptune-s-fix-any-tianeptine-product-due-serious-risks-14633.html"
  ["blog_url"]=>
  string(124) "https://www.drugs.com/fda/fda-warns-consumers-not-purchase-neptune-s-fix-any-tianeptine-product-due-serious-risks-14633.html"
  [15]=>
  string(19) "2023-11-21 19:33:00"
  ["add_date"]=>
  string(19) "2023-11-21 19:33:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}